50results about How to "Reduce myocardial infarct size" patented technology

The invention relates the use of codonopsis pilosula and astragalus root composition in treating ischemic heart diseases, wherein the composition has functions for treating myocardial ischemia, myocardiac infarction, myocardiopathy, and for treating thrombogenesis, lowering blood viscosity, and reducing platelet aggregation.

The invention provides a new application of miRNA-484, a pharmaceutical composition containing miRNA-484 and the application thereof. The use of the miRNA-484 in the preparation of medicines for preventing or treating heart disease, the pharmaceutical composition, the pharmaceutical composition is composed of an effective dose of miRNA-484 pharmaceutically acceptable carrier, virus or auxiliary material. miRNA-484 has a protective effect on the heart by inhibiting cardiomyocyte apoptosis, and miRNA-484 has potential preventive and therapeutic value for many heart diseases.

The Chinese medicine composition for treating coronary heart disease and angina pectoris consists of two kinds of Chinese medicinal materials, red peony root and corydalis tuber, or consists of red peony glycosides extracted from red peony root and corydalis total alkaloid extracted from corydalis tuber. The Chinese medicine composition may be prepared into various pharmaceutically acceptable preparation forms for treating coronary heart disease and angina pectoris, and is safe, effective, stable and convenient.

The invention discloses use of benzisoselenazolones, particularly compounds represented by the general formula (I) against ischemic myocardial injury. The compounds are characterized by selectively inhibiting Na⁺/Ca²⁺ exchange, dilating coronary artery and decreasing myocardial oxygen consumption, which possess the advantages of high activity, potent specificity and low toxicity.

A powder injection of haw leaf general flavone for treating cardiovascular and cerebrovascular diseases is prepared from the haw heaf general flavone (20-85 wt.%) and water-soluble medical auxiliaries (15-80 wt.%). Its advantages are high curative effect, stability and biologic utilization rate, and quickly taking its effect.

The invention provides a traditional Chinese medicine extract for treating ischemic heart disease, and a preparation method thereof. The extract is prepared from 5-800 parts by weight of figwort root and 10-1500 parts by weight of honeysuckle as raw materials. Proven by experiments, the extract provided by the invention has obvious effects, can reduce the infarct size induced by myocardial ischemia after coronary artery ligation of rats, and can relieve arrhythmia caused by aconitine on mice, ouabin on guinea pigs and coronary artery ligation on rats. Therefore, the extract can be used for treating ischemic heart disease and arrhythmia.

A semi-solid skeleton composition of ginkgo leaf extract for treating coronary heart disease, angina pectoris, hyperlipemia and cerebrovascular disease, and preventing sanile dementia and cancer contains the ginkgo leaf extract (2-20 wt.%), surfactant (1-45 wt.%) and semi-solid skeleton carrier (40-92 wt.%). Its advantages are high biologic utilization rate and low dosage.

An objective of the present invention is to provide methods for producing progenitor cells which show a high proliferation ability ex vivo and promote neovascularization or myocardium regeneration, by culturing pluripotent cells in a medium containing adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). Moreover, another objective of the present invention is to provide the progenitor cells and uses thereof. In order to solve the above problems, the inventors of the present application have successfully developed a novel culture technique for producing progenitor cells from adipose tissues more efficiently compared to the conventional techniques, by using adrenomedullin (AM) and/or vascular endothelial growth factor (VEGF). The progenitor cells produced by the present inventors are specialized cells having a potent proliferation ability, a revascularization ability, and a myocardium regeneration ability, and have the property of not differentiating into adipocytes even if subjected to differentiation induction into adipocytes. Therefore, the progenitor cells of the present invention can be effective pharmaceutical agents for intractable diseases in the brain, lung, liver, kidney and the like.

The invention discloses a novel application for angelica polymorpha maxim and the extract thereof. The inventor proves via experiments that angelica polymorpha maxim extracts with different dosages can be used for effectively preventing or relieving the myocardial damages caused by myocardial ischemia reperfusion after being orally administrated in advanced.

The invention discloses a Xuesaitong pharmaceutical composition and a preparation method, a preparation and application thereof. The Xuesaitong pharmaceutical composition is prepared from the following components in percentage by mass: 0.001 to 99.996% of ginsenoside Rb2, 0.001 to 99.996% of ginsenoside Rb1, 0.001 to 99.996% of ginsenoside Rg1, 0.001 to 99.996% of ginsenoside Rc, and 0.001 to 99.996% of notoginsenoside R1. The Xuesaitong pharmaceutical composition and the preparation have the advantages that the obvious treatment effect on ischemic cardiovascular and cerebrovascular diseases of myocardial infarction, cerebral apoplexy, cerebral infarction, brain hemiplegia and the like, and the retinopathy or optic nerve injury disease due to ischemic cardiovascular and cerebrovascular diseases, diabetes and the like is realized, and the application prospect is broad; compared with the prior art and the product, the treatment effect is better, the safety is higher, and the requirementof clinical medicine usage can be well met; the technology of the preparation method is simple, the conditions are mild, the operation is convenient, the quality is stable and controllable, and the preparation method is suitable for industrialized large-scale production.

The invention discloses o-nitro caffeic acid phenethyl ester with a structural formula shown as formula I. The method includes: subjecting caffeic acid and thionyl chloride to acylation reaction to generate caffeoyl chloride, then in the presence of a catalyst, subjecting the caffeoyl chloride and o-nitrophenylethanol to esterification reaction in an organic solvent, thus obtaining o-nitro caffeic acid phenethyl ester. Compared with caffeic acid phenethyl ester, the o-nitro caffeic acid phenethyl ester has better effect of protecting antioxidant enzyme activity, stronger ability of clearing oxygen free radicals, and better effects of maintaining antioxidant ability of myocardial cells, protecting normal cell structure and alleviating cell oxidative damage, can significantly reduce ischemia/reperfusion myocardial cell apoptosis, decreases myocardial infarction area, can be used for preparation of drugs for improving ischemia reperfusion injury, and plays an important role in treatment of cardiovascular system diseases. (formula I).

The invention relates to a pharmaceutical composition containing miRNA-324 and application of the pharmaceutical composition. The pharmaceutical composition comprises an effective dose of miRNA-324 and pharmaceutically acceptable vectors, viruses or accessories, wherein the vectors are cholesterol, cholesterin, lipidosome or nano-particles; the sequence of miRNA-324 antisense nucleotide is 5'-CGCAUCCCCUAGGGCAUUGGUGU-3'. The pharmaceutical composition is used for treating the heart disease such as myocardial infarction, myocardial ischemial injury, myocardial hypertrophy or myocardial fibrosis in an oral taking or injection manner. The pharmaceutical composition has the beneficial effects that the preparation process is simple, the pharmaceutical effect is obvious, the use is convenient, and the treatment is environmentally friendly.

The invention belongs to the medicinal field and particularly relates to a pharmaceutical composition for treating myocardial ischemia, in particular to the pharmaceutical composition for treating myocardial ischemia and a preparation method of the pharmaceutical composition. The pharmaceutical composition is prepared from the following traditional Chinese medicine materials in parts by weight: 20-40 parts of pseudo-ginseng, 10-30 parts of radix clematidis, 10-30 parts of long peppers, 20-40 parts of peach kernels, 20-40 parts of cassia twigs, 10-30 parts of dried tangerine or orange peel, 10-30 parts of paris polyphylla, 15-35 parts of elderberry, 20-40 parts of astragalus, 5-15 parts of myrrh, 15-35 parts of herba epimedii and 15-35 parts of prepared rehmannia roots. The pharmaceutical composition disclosed by the invention is safe and effective, simple in preparation process, free of toxic or side effects, relatively high in compliance of a patient, and very good in development and application prospect.

The invention provides an Alda-1 solution as well as a preparation method and application thereof. According to the solution, Alda-1 is adopted as an active component, ethanol, polyethylene glycol 400and normal saline are adopted as solvents, and the problems that Alda-1 is poor in solubility and cannot be clinically used can be solved. The Alda-1 solution provided by the invention can be used asan injection for intravenous injection, heart functions can be well improved, in addition, the stability is good, the security is high, no hemolysis can be caused, and in addition, the solution has no conspicuous irritation to blood vessels in intravenous injection with dilution of the normal saline in a ratio of 1:1.

An application of recombinant human granulocyte colony stimulating factor in preparing medicine for treating myocardial infaction is disclosed. Its advantages are high curative effect and safety, and low cost.

The invention relates to a medicine for preventing and treating myocardial ischemia and a preparation method and application thereof, in particular to a compound with a formula (I) and a pharmaceutically acceptable salt thereof. The formula (I) is shown in the description. The compound with the formula (I) has the advantages that the excellent myocardial ischemia resisting function is realized; in a rat acute myocardial infarction model, the compound can obviously reduce the myocardial infarction area of the rat with the myocardial infarction, and the activities of CK (creatine kinase), AST (aspartate aminotransferase) and LDH (lactate dehydrogenase) in serum are obviously reduced; the function of preventing and treating the myocardial infarction is obvious, and the medicine can be applied to prevent and treat the myocardial infarction.

The invention discloses a pharmaceutical composition for treating cardiovascular diseases and a preparation method thereof. The pharmaceutical composition comprises the following raw materials in parts by weight: 50-200 parts of a danshen root extract, 30-120 parts of panax notoginseng total saponins, 30-120 parts of a bitter orange extract, 30-200 parts of a Chinese angelica extract, 30-200 parts of a ginger extract, 5-40 parts of a Chinese angelica volatile oil inclusion compound and 5-40 parts of a ginger volatile oil inclusion compound. The preparation method comprises the following steps: preparing the danshen root extract, preparing the panax notoginseng total saponins, preparing the bitter orange extract, preparing the Chinese angelica and ginger extracts, preparing the Chinese angelica and ginger volatile oil inclusion compounds, and mixing the raw materials. The pharmaceutical composition disclosed by the invention has the positive effects that the active ingredients of each medicinal material are fully extracted and purified, the usage amount of a solvent is relatively small, the time is saved, and the production cost is reduced. The pharmaceutical composition can be used for effectively treating ischemic heart diseases of coronary heart disease, angina pectoris, miocardial infarction and the like, and also has the effect of reducing the blood pressure and blood fat.

The invention provides a circular RNAcircTTC3 overexpression adeno-associated virus vector, an adeno-associated virus and application of the adeno-associated virus, and belongs to the technical field of biological medicine. The cyclic RNA-circTTC3 delivered by using the AAV9 virus vector can be used for preparing a medicine for preventing and/or treating myocardial ischemia-reperfusion injury (IRI). The gene sequence capable of transcribing the circular RNA-circTTC3 is delivered to the heart tissue based on the AAV virus, and is stably and highly expressed in the heart tissue, the circTTC3 is up-regulated to generate a heart protection effect, and the myocardial infarction area is effectively reduced, so that the effect of protecting myocardial infarction is achieved. According to the application disclosed by the invention, circTTC3 is over-expressed in primary myocardial cells of newborn rats, and the circTTC3 is found to be capable of remarkably promoting proliferation and growth of the primary myocardial cells of the newborn rats.